News Center
Featured
ACELYRIN, INC. Furthers Leadership Position in Immunology with Transformative Acquisition of ValenzaBio...
The acquisition of ValenzaBio adds multiple clinical and pre-clinical development programs to ACELYRIN’s robust immunology pipeline, which is led by izokibep.
ACELYRIN, INC. Announces Izokibep Achieves HiSCR100 Responses at 12 Weeks in Moderate-to-Severe Hidradenitis Suppurativa
Press Release
ACELYRIN, INC. Announces Izokibep Achieves HiSCR100 Responses at 12 Weeks in Moderate-to-Severe Hidradenitis Suppurativa
Read more 
ACELYRIN, INC. Furthers Leadership Position in Immunology with Transformative Acquisition of ValenzaBio
Press Release
ACELYRIN, INC. Furthers Leadership Position in Immunology with Transformative Acquisition of ValenzaBio
Read more ACELYRIN, INC. to Accelerate Development of Izokibep in Hidradenitis Suppurativa
Press Release
ACELYRIN, INC. to Accelerate Development of Izokibep in Hidradenitis Suppurativa
Read more Former Merck Commercial President Dawn Svoronos joins ACELYRIN, INC. Board of Directors
Press Release
Former Merck Commercial President Dawn Svoronos joins ACELYRIN, INC. Board of Directors
Read more ACELYRIN, INC. Hosts KOL Panel Discussion at ACR Convergence 2022 on Role of Enthesitis in PsA and AxSpA
News
ACELYRIN, INC. Hosts KOL Panel Discussion at ACR Convergence 2022 on Role of Enthesitis in PsA and AxSpA
Read more ACELYRIN, INC. Announces Phase 2 Data for Izokibep in Psoriatic Arthritis That Demonstrate Broad Clinical Efficacy – including in Difficult-to-Treat Manifestations – Driving Meaningful Benefits for Patients Such as Improved Pain, Sleep, and Physical Function
Press Release
ACELYRIN, INC. Announces Phase 2 Data for Izokibep in Psoriatic Arthritis That Demonstrate Broad Clinical Efficacy – including in Difficult-to-Treat Manifestations – Driving Meaningful Benefits for Patients Such as Improved Pain, Sleep, and Physical Function
Read more ACELYRIN, INC. Announces $300 Million Series C Financing to Accelerate Phase 3 Development of Izokibep, a Unique IL-17A Inhibitor to Treat Inflammatory Diseases
Press Release
ACELYRIN, INC. Announces $300 Million Series C Financing to Accelerate Phase 3 Development of Izokibep, a Unique IL-17A Inhibitor to Treat Inflammatory Diseases
Read more